Investor Conference Call World Congress of Cardiology - Rivaroxaban Review

Tuesday, September 5, 2006
Start at approx. 6:00 p.m. CEST (4:00 p.m. GMT)


Dr. Gunnar Riemann
President of the Pharmaceuticals Division

Dr. Frank Misselwitz
Head Therapeutic Area Cardiovascular, Global Clinical Development

The audio recording of this event is no longer available.

World Congress of Cardiology 2006 Abstracts on Rivaroxaban:

Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study (Abstract P4568)

Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study (Abstract P4569)

Antithrombotic effects of rivaroxaban - an oral, direct Factor Xa inhibitor - in animal models of arterial and venous thrombosis: comparison with enoxaparin, an antithrombin-dependent anticoagulant (Abstract P4571)

Last updated: January 09, 2014 Copyright © Bayer AG